Navigation Links
Researchers discover new way to kill pediatric brain tumors
Date:2/9/2010

Researchers at Washington University School of Medicine in St. Louis have shown once again that "ready, fire, aim," nonsensical though it may sound, can be an essential approach to research.

The scientists robotically "fired" 2,000 compounds into culture plates containing tumor cells to see if the compounds had any effect. When the robotic screener found one substance had scored a hit by inhibiting growth of the tumor cells in its plate, researchers analyzed what that compound acted against. Follow-up studies showed that the drug slowed tumor growth in mice by inhibiting the function of a protein called STAT3.

As a result, researchers now have a previously unrecognized target, STAT3, at which they can "aim" new drugs for the treatment of cancer in neurofibromatosis-1 (NF1), a genetic condition that causes increased risk of benign and malignant brain tumors.

"We were excited to find that the slowed tumor growth we observed following treatment resulted from increased tumor cell death an effect we hadn't seen before when we blocked other NF1 growth control molecules," says senior author David H. Gutmann, M.D., Ph.D., the Donald O. Schnuck Family Professor of Neurology. "Now we can identify the genes that STAT3 influences to fine-tune our treatments and ensure that we kill cancer cells with minimal harm to normal cells."

Gutmann is director of the Neurofibromatosis Center at Washington University, a national referral center for patients with all forms of neurofibromatosis. The center is active both in clinical trials and in basic research to help develop innovative new approaches for treating patients with NF. Gutmann is also co-director of the neuro-oncology program at the Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital.

Gutmann collaborated on this project with David Piwnica-Worms, M.D., Ph.D., professor of radiology and of developmental biology and director of the Molecular Imaging Center at Washington University. The results appear this month in the journal Cancer Research.

Cucurbitacin-I, the compound that led scientists to STAT3, is a plant steroid. It belongs to a family of bitter-tasting compounds previously identified as inhibitors of STAT3. Gutmann says cucurbitacin-I is likely too toxic to be suitable for use in clinical trials at this time.

After the successful robotic test of cucurbitacin-I, researchers showed that STAT3, which turns on and off the activity of a number of genes, is unusually active in NF1 tumor cells. Further investigation revealed that STAT3 activity is regulated by another gene very familiar to Gutmann: the mammalian target of rapamycin (mTOR).

Gutmann's laboratory linked mTOR and the processes it controls to NF1 years ago. The new connection between STAT3 and the mTOR pathway makes STAT3 the last link in a chain of molecules that take growth-promoting signals from the cell membrane to the nucleus. Gutmann says he is encouraged by the possibility that scientists might be able to decipher the genetic program controlled by STAT3 in order to develop more refined treatments for tumors in patients with NF1.

"We went in with a 'we don't know enough' approach, let's try 'ready, fire, aim,' and it paid off," he says.


'/>"/>
Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
Source:Eurekalert

Related medicine news :

1. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
2. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
3. UCSF Researchers Identify Regulator of Human Sperm Cells
4. Researchers find broad spectrum antiviral that fights multitude of viruses
5. Caregivers of ICU patients are collateral damage of critical illness, say Pitt researchers
6. Researchers fight world hunger by mapping the soybean genome
7. HIV researchers solve key puzzle after 20 years of trying
8. UC Davis researchers identify brain protein for synapse development
9. UCLA cancer researchers perform complete genomic sequencing of brain cancer cell line
10. Researchers find new way to study how enzymes repair DNA damage
11. UCLA researchers image earliest signs of Alzheimers, before symptoms appear
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... ... leakage is revolutionizing the way women look and feel about themselves and their ... of female sexual dysfunction and urinary leakage head on with a ground breaking ...
(Date:6/26/2017)... ... June 26, 2017 , ... New patients with missing teeth ... with or without a referral. Dr. Cotey is a trusted dentist who has placed ... replacement option. , Patients with missing teeth in Fitchburg, WI, are encouraged to find ...
(Date:6/25/2017)... (PRWEB) , ... June 25, 2017 , ... An increase ... and growing foliage and plants, and along with that; a humdinger of an allergy ... sufferers, it also means an increase in misery-causing grass and weed pollen. , ...
(Date:6/24/2017)... ... June 24, 2017 , ... ... genetic testing for medications in select Florida and Texas doctors' offices and clinics. ... This new application of genetic testing recognizes the role genes play in determining ...
(Date:6/24/2017)... Killeen, TX (PRWEB) , ... June 24, 2017 , ... ... can boost home security, such as getting a guard dog or having an alarm ... homes simply aren’t secure against forced entry. Yair Frenkel, owner of TX Premier Locksmith ...
Breaking Medicine News(10 mins):
(Date:6/20/2017)... LAGUNA HILLS, Calif. , June 20, ... data that validate the use of MMprofiler with SKY92, ... multiple myeloma (MM). In a poster presentation at the ... (EHA) in Madrid, Spain , SkylineDx ... identifying high-risk elderly patients. In a ...
(Date:6/16/2017)... , June 16, 2017 Datascope Corp. is voluntarily performing ... Corp. for a potential electrical test failure code.     ... PART NUMBER ... CS300 IABP 0998-UC-0446HXX; ... This ...
(Date:6/14/2017)... CALABASAS, Calif. , June 14, 2017 ... with the City of Fremont ... chain of the bio-pharma industry in California ... sharing technology, enabling executive networking, and fostering workforce development. ... the development and growth of start-ups, as well as ...
Breaking Medicine Technology: